During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...

RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers ...

Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value as off-the-shelf options for patients post chimeric antigen receptor ...

Anixa Biosciences' breast cancer vaccine elicited targeted immune responses in 70% of patients. Click here to read an ...

MiNK Therapeutics surged on tumor remission data for agenT-797, but financial risks and limited clinical proof remain. Learn ...

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T ...

Despite the increasing sophistication of anticancer therapies, many malignancies continue to evade treatment. T cells expressing chimeric antigen receptor (CAR) can effectively attack some tumors by ...

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) -- as well as three neonatal fragment ...

I’ve endured numerous rounds of radiation and taken thousands of pills—but CAR-T is the most effective therapy I’ve completed ...